Aristea Therapeutics, a San Diego, CA-based clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, secured $15M in Series A funding.
Novo Holdings A/S made the investment. In connection with the financing, Tiba Aynechi, Ph.D and Ken Harrison, Ph.D from Novo Ventures (US), joined Aristea’s Board of Directors.
Led by James Mackay, President and CEO, Aristea Therapeutics is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. Its lead program, RIST4721, is currently in Phase 2 clinical development. Aristea has also obtained exclusive global rights to its lead program RIST4721, from AstraZeneca.
The company plans to initiate a Phase 2 clinical study in early 2019.
Mackay was formerly President and CEO of Ardea Biosciences (acquired by AstraZeneca in 2012).